Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Julie A. Lovshin(Sunnybrook Health Science Centre), David Z.I. Cherney(University Health Network), Michael H. Brent(University of Toronto), Leif Erik Lovblom(Mount Sinai Hospital), Josephine Tse(University Health Network), Hillary A. Keenan(Joslin Diabetes Center), Petter Bjornstad(University of Colorado Denver), Alanna Weisman(Mount Sinai Hospital), Leslie Cham(University Health Network), Vesta Lai(University Health Network), Narinder Paul(University Health Network), Yuliya Lytvyn(University Health Network), Mohammed A. Farooqi(Mount Sinai Hospital), Andrej Orszag(University of Toronto), Vera Bril(University Health Network), Bruce A. Perkins(Sinai Health System), Geneviève Boulet(University of Toronto), Daniel Scarr(Mount Sinai Hospital)
Cited by 55
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
State of the Art: Iterative CT Reconstruction Techniques
|Radiology|2015|704
Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study
|Diabetes|2010|497
Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction
|Nature Medicine|2017|493
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470